Company profile: Silvergate Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pediatric medications, developing and commercializing innovative oral solutions that improve dosing accuracy, safety, and availability. Products include Xatmep (methotrexate) for pediatric acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis; Qbrelis (lisinopril) for hypertension (adults/pediatric 6+), adjunct heart failure, and acute MI in adults; and EPANED (enalapril) for hypertension (adults/pediatric >1 month), symptomatic heart failure, and asymptomatic left ventricular dysfunction.
Products and services
- EPANED: Pediatric-formulated oral solution of enalapril maleate for adults and children older than 1 month, treating hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction with liquid dosing
- Qbrelis: Clinical-grade oral lisinopril solution indicated for hypertension in adults and pediatric patients ≥6 years, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults
- Xatmep: Pediatric-focused oral solution of methotrexate for pediatric patients, indicated for the treatment of acute lymphoblastic leukemia and management of polyarticular juvenile idiopathic arthritis.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Silvergate Pharmaceuticals
Baylis Medical
HQ: Canada
Website
- Description: Provider of high-technology cardiology, endovascular, and oncology products, specializing in RF transseptal access and puncture systems that create controlled perforations in cardiac and vascular tissues. Products include NRG RF Transseptal Kit and Needle, SupraCross RF Transseptal Solution, VersaCross steerable access solutions, and SureFlex steerable guiding sheaths.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Baylis Medical company profile →
FineHeart
HQ: France
Website
- Description: Provider of France-based innovative cardiovascular medical devices, including the FLOWMAKER®, a fully implantable, wirelessly powered mechanical circulatory support device that optimizes cardiac output while preserving heart contractility. Offers ICOMS FLOWMAKER® clinical trials to evaluate safety and performance in advanced heart failure, and partners with Lauak Group to manufacture pump parts, with final assembly in-house.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FineHeart company profile →
Zerusa
HQ: Ireland
Website
- Description: Provider of minimally invasive medical devices for the diagnosis and treatment of vascular disease, designed, developed, and marketed by Zerusa Limited.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zerusa company profile →
Reprieve Cardiovascular
HQ: United States
Website
- Description: Provider of personalized decongestion and automated fluid management for acute decompensated heart failure, offering the Reprieve System, Personalized Volume Management System, and Guided Diuretic Therapy to tailor diuretic dosing, speed fluid removal and symptom relief, prevent hypotension, maintain renal function, and reduce readmissions; also conducting the FASTR trial comparing Reprieve therapy to optimized diuretics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reprieve Cardiovascular company profile →
AtheroMed
HQ: United States
Website
- Description: Provider of peripheral atherectomy catheter systems to enhance treatment of below-the-knee disease; develops treatments for peripheral arterial disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AtheroMed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Silvergate Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Silvergate Pharmaceuticals
2.2 - Growth funds investing in similar companies to Silvergate Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Silvergate Pharmaceuticals
4.2 - Public trading comparable groups for Silvergate Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →